Evidence map›Paper›PMID 37805563›Full record

ReviewOrphanet journal of rare diseases2023

Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective.

Philippe F Backeljauw, Mary Andrews, Peter Bang, Leo Dalle Molle, Cheri L Deal, Jamie Harvey, Shirley Langham, Elżbieta Petriczko, Michel Polak, Helen L Storr and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 6 countries.

Philippe F BackeljauwCincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Philippe.Backeljauw@cchmc.org.
Mary AndrewsThe Major Aspects of Growth in Children (MAGIC) Foundation, Warrenville, IL, USA.
Peter BangDivision of Children's and Women's Health, Department of Biomedical and Clinical Sciences (BKV), Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Leo Dalle MolleCaregiver Representative, Cincinnati, OH, USA.
Cheri L DealUniversité de Montréal, Montréal, QC, Canada.
Jamie HarveyThe Major Aspects of Growth in Children (MAGIC) Foundation, Warrenville, IL, USA.
Shirley LanghamPaediatric Endocrinology, Great Ormond Street Hospital UCL Hospitals, London, UK.
Elżbieta PetriczkoDepartment of Paediatrics, Endocrinology, Diabetology, Metabolic Disorders, and Cardiology of Developmental Age, Pomeranian Medical University, Szczecin, Poland.
Michel PolakDepartment of Pediatric Endocrinology, Gynecology and Diabetology, Hôpital Universitaire Necker Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France.
Helen L StorrCentre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Mehul T DattaniPaediatric Endocrinology, Great Ormond Street Hospital UCL Hospitals, London, UK. m.dattani@ucl.ac.uk.ORCID http://orcid.org/0000-0002-0365-5809
Great Ormond Street Hospital · GBCentre Hospitalier Universitaire Sainte-Justine · CACincinnati Children's Hospital Medical Center · USHôpital Necker-Enfants Malades · FRLinköping University · SEPomeranian Medical University · PLQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere primary insulin-like growth factor-I (IGF-I) deficiency (SPIGFD) is a rare growth disorder characterized by short stature (standard deviation score [SDS] ≤ 3.0), low circulating concentrations of IGF-I (SDS ≤ 3.0), and normal or elevated concentrations of growth hormone (GH). Laron syndrome is the best characterized form of SPIGFD, caused by a defect in the GH receptor (GHR) gene. However, awareness of SPIGFD remains low, and individuals living with SPIGFD continue to face challenges associated with diagnosis, treatment and care.

objectiveTo gather perspectives on the key challenges for individuals and families living with SPIGFD through a multi-stakeholder approach. By highlighting critical gaps in the awareness, diagnosis, and management of SPIGFD, this report aims to provide recommendations to improve care for people affected by SPIGFD globally.

methodsAn international group of clinical experts, researchers, and patient and caregiver representatives from the SPIGFD community participated in a virtual, half-day meeting to discuss key unmet needs and opportunities to improve the care of people living with SPIGFD.

resultsAs a rare disorder, limited awareness and understanding of SPIGFD amongst healthcare professionals (HCPs) poses significant challenges in the diagnosis and treatment of those affected. Patients often face difficulties associated with receiving a formal diagnosis, delayed treatment initiation and limited access to appropriate therapy. This has a considerable impact on the physical health and quality of life for patients, highlighting a need for more education and clearer guidance for HCPs. Support from patient advocacy groups is valuable in helping patients and their families to find appropriate care. However, there remains a need to better understand the burden that SPIGFD has on individuals beyond height, including the impact on physical, emotional, and social wellbeing.

conclusionsTo address the challenges faced by individuals and families affected by SPIGFD, greater awareness of SPIGFD is needed within the healthcare community, and a consensus on best practice in the care of individuals affected by this condition. Continued efforts are also needed at a global level to challenge existing perceptions around SPIGFD, and identify solutions that promote equitable access to appropriate care. Medical writing support was industry-sponsored.

Indexed as

DwarfismLaron SyndromeGrowth DisordersHumansInsulin-Like Growth Factor IQuality of LifeInsulin-Like Growth Factor IDiagnosisGrowth hormone insensitivity (GHI)Insulin-like growth factor-I (IGF-I)Laron syndromeQuality of lifeSevere primary IGF-I deficiency (SPIGFD)Short statureTreatment

Identifiers

PMID37805563
PMCPMC10559630
OpenAlexW4387428176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.